A 10 anni dalla pubblicazione dello studio " Women’s Health Initiative» (WHI)", ampiamente riportato da tutti i media, una commissione d'esperti europei e americani ha trovato un accordo ed emanato le nuove direttive sulla terapia sostitutiva ormonale (TOS). Queste sono state pubblicate sotto il titolo "Global consensus statement on menopausal hormone therapy" sulla prestigiosa rivista Climateric (organo ufficiale della società internazionale sulla menopausa) nel mese d'aprile 2013.
I vantaggi della TOS per la salute sono chiaramente superiori ai rischi, se la terapia è iniziata subito dopo la menopausa, collocandosi saggiamente in quella finestra di opportunità (“window of opportunity”), ormai ben evidenziata in tutte le ri-analisi anche del controverso studio WHI(Women’s Health Initiative Study) e dalle analisi successive fino ad oggi.
Riassumendo potremmo dire che l'indicazione alla TOS è una decisione individuale e non dovrebbe essere introdotta a più di 10 anni dalla diagnosi di menopausa. La dose ed i dosaggi sono individuali, la durata è indeterminata, ma può variare da persona a persona e va rivalutata di anno in anno. Bibliografia
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. JAMA 2002; 288:321-33.
Global consensus statement on menopausal hormone therapy. Climacteric 2013;16:203-4.
Schneider H. The view of the International Menopause Society onf the Women’s Health Initiative. Climacteric 2002;5:211-6.
The North American Menopause Society. Estrogen and progestogen use in postmenopausal women : 2012 Position Statement of the North American Menopause Society. Menopause 2012;19;257-71.
Panay N, Fenton A. Has the time for the definitive, randomized, placebo-controlled HRT trial arrived ? Climacteric 2011;14:195-6.
Fenton A, Panay N. The Women’s Health Initiative – a decade of progress. Climacteric 2012;15:205.
Langer RD, Manson JE, Allison MA. Have we come full circle – or moved forward ? The Women’s Health Initiative 10 years on. Climacteric 2012;15:206-12.
Kolata G. Study is halted over rise seen in cancer risk. New York Times, July 9, 2002. www.nytimes.com/2002/07/09/us/study-is-halted-over-rise-seen-in-cander-risk.Html?pagewanted=all.
Pines A, Sturdee DW, MacLennan AH. Quality of life and the role of menopause therapy. Climacteric 2012;15:213-6.
Hodis HN, Collins R, Mack WJ, Lind Schierbeck L. The timing hypothesis for coronary heart disease prevention with hormone therapy : Past, present and future in perspective. Climacteric 2012;15:217-28. [Me
Archer DF, Oger E. Estrogen and progestogen effect on venous thromboembolism in menopausal women. Climacteric 2012;15:235-40.
Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241-9.
Maki P, Henderson VW. Hormone therapy, dementia, and cognition: The Women’s Health Initiative 10 years on. Climacteric 2012;15:256-62.
De Villiers TJ, Stevenson JC. The WHI: The effect of hormone replacement therapy on fracture prevention. Climacteric 2012;15:263-6.
Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012;15:267-74.
Burger HG, MacLennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women’s health. Climacteric 2012;15:281-7.
Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: Perspectives 10 years after the Women’s Health Initiative. Climacteric 2012;15:229-34.
Reid RL, Blake J, Abramson B, Khan A, Senikas V, Fortier M (2009) Menopause and Osteoporosis update 2009. Society of Obstetricians and Gynecologists of Canada (SOGC). Clinical Practice Guideline. J Obstet Gynecol Can 222:S1-S52
Dennerstein L, Lehert P, Koochaki PE, Graziottin A, Leiblum S, Alexander JL (2007) A symptomatic approach to understanding women’s health experiences: a cross-cultural comparison of women aged 20-70 years. Menopause 14:688-696
Joffe H, Hall JE, Soares CN, Hennen J, Reilly CJ, Carlson K, Cohen LS (2002) Vasomotor symptoms areassociated with depression in perimenopausal women seeking primary care. Menopause 9(6): 392–398
Rocca WA, Bower JH, Maragone DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ (2007)Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69(11):1074-1083
Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd (2008) Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology70(3):200-209
Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L, Pieri M, Genazzani AD, Luisi S, Genazzani AR (2007) Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod 22(4):995-1002
Freeman EW, Sammel MD, Lin H, Nelson DB (2006) Associations of hormones and menopausal statuswith depressed mood in women with no history of depression. Arch Gen Psychiatry 63(4):375-382 Pae CU, Mandelli L, Kim TS, Han C, Masand PS, Marks DM, Patkar AA, Steffens DC, De Ronchi D, Serretti A (2009) Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women:a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother 63 (3):228-235 Epub 2008 Apr 30